Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Research & Development (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Research & Development for 16 consecutive years, with $29.0 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 46.2% to $29.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $109.3 million through Dec 2025, up 46.81% year-over-year, with the annual reading at $109.3 million for FY2025, 46.81% up from the prior year.
  • Research & Development hit $29.0 million in Q4 2025 for Vanda Pharmaceuticals, up from $22.6 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $35.7 million in Q1 2025 to a low of $16.1 million in Q1 2021.
  • Historically, Research & Development has averaged $21.1 million across 5 years, with a median of $20.0 million in 2021.
  • Biggest five-year swings in Research & Development: soared 5423.14% in 2021 and later crashed 33.22% in 2023.
  • Year by year, Research & Development stood at $19.3 million in 2021, then dropped by 4.54% to $18.5 million in 2022, then skyrocketed by 31.89% to $24.3 million in 2023, then dropped by 18.48% to $19.8 million in 2024, then skyrocketed by 46.2% to $29.0 million in 2025.
  • Business Quant data shows Research & Development for VNDA at $29.0 million in Q4 2025, $22.6 million in Q3 2025, and $22.0 million in Q2 2025.